INTERIM REPORT

1/1-31/3 2021

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.

2curex

FOCUS ON BUSINESS DEVELOPMENT AND GO-TO-MARKET

In the first quarter of 2021, and with the momentum created by the TICC trial results, 2cureX has accelerated its Business development and Go-to-Market activities. We have added four countries (Italy, France, Spain and Poland) to our 2021 priorities and are in advanced discussions with distributors there. We are having regular meetings with hospitals in the different countries to identify early adopters and discuss programs to facilitate the introduction of IndiTreat® in their clinical routine, and we have also initiated the activities towards application for reimbursement in Germany and UK.

At the same time, we are working on changes in our quality and regulatory processes and documents in order to adapt to the new IVD Regulation coming into force in May 2022.

FINANCIAL HIGHLIGHTS

With a cash position of SEK 54 million at the end of Q1 2021, 2cureX continues to hold a strong financial position that can support the activities and growth ambitions of the current plans.

(KSEK) if not stated otherwise	**Q1 2021** *1/1-31/3*	**Q1 2020** *1/1-31/3*	**2020** *1/1-31/12*
Net sales	0	0	0
Other operating income	3 850	2 603	15 391
Profit before tax	-2 222	-1 229	-8 591
Earnings per share*	-0,12	-0,09	-0,54
Equity ratio**	94%	81%	93%
Cash and bank	53 991	30 018	58 577
Average number of shares	14 856 600	12 240 000	13 604 775
No. of shares by the end of the period	14 856 600	12 240 000	14 856 600

**Earnings per share: Profit for the period divided by the average number of shares.*

***Equity ratio: Shareholder's equity divided by total capital.*

SIGNIFICANT EVENTS IN Q1 2021

Q1 2021

JAN

- 2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
- The last patient had been treated in 2cureX's interventional clinical trial (TICC) in metastatic colorectal cancer
- 2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO

FEB

- IndiTreat® selected to prestigious multinational ovarian cancer project (DECIDER)

MAR

- The clinical TICC trial met its primary endpoint

EVENTS AFTER THE PERIOD

APR

- The exercise price for warrants of series TO1 determined to SEK 13.22
- Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
- 2cureX's CEO Fernando Andreu is buying shares in the company

MAY

- Mangold Fondkommission AB published an Analyst Report on 2cureX
- Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million.

FOR MORE INFORMATION PLEASE CONTACT:

Fernando Andreu, CEO
Mail: fa@2curex.com
Mobile: +45 2279 5399

Ole Thastrup, CSO
Mail: fa@2curex.com
Mobile: +45 2211 5399

www.2curex.com

LETTER FROM THE CEO

The first quarter of 2021 has seen a decisive change in the orientation of the company, with a stronger focus in Business Development and Go-to-Market activities

BUILDING ON A STRONG LEGACY

On February 1st, 2021 I became the CEO of 2cureX. This appointment reflects a transition in the company focus. In the previous years, the company had concentrated in creating and optimizing the technology behind IndiTreat®, and more recently in developing the first application for it, a test to support treatment decision-making in third line metastatic colorectal cancer. In 2021, with a product already in the market, the company had to strengthen its commercial and service delivery capabilities and looked for a CEO and CFO who were experienced in those areas.

The transition comes in the year of the 15th anniversary of 2cureX. Back in 2006, Precision Oncology was in its early stages, and everyone in the field was focusing on genetic biomarkers. Understanding the limitations of this approach and looking at Functional Testing to overcome them was visionary back then. Sticking to that idea, strongly backed by key opinion leaders and financially supported by numerous EU grants, 2cureX conducted years of experiments, technology assessments and development projects that finally crystalized at the end of 2020 in our first product and represents a very strong foundation to build our future upon.

ENDORSEMENT OF INDITREAT® FUNCTIONAL PRECISION ONCOLOGY TESTS

In the first quarter of 2021 we have seen two events that represented a strong endorsement of the IndiTreat® technology and of 2cureX.

In February DECIDER (https://www.deciderproject.eu/), a research project to address chemotherapy-resistant ovarian cancer funded by the EU under Horizon 2020, chose 2cureX as the expert partner in Functional Testing, joining a team of prestigious research groups and companies located in 7 European countries. This project is an accelerator of our efforts to develop IndiTreat® tests for ovarian cancer.

In March, the Principal Investigator of the TICC trial communicated that the study had fulfilled its primary goal. TICC is a prospective, interventional trial in metastatic colorectal cancer. This study has proven that the number of patients with stabilized disease after eight weeks of treatment doubles compared to standard-of-care, when IndiTreat® is used for selecting the therapy. The results have been submitted to ASCO [1)] and the abstract has been published on May 19th 2021. This is the first direct confirmation of the value of IndiTreat® in clinical practice and the basis to start the commercial rollout of our first product, IndiTreat® mCRC 3L for metastatic colorectal cancer in third line of treatment.

Details on these two events can be found in dedicated sections in the following pages.

ACCELERATING GO-TO-MARKET ACTIVITIES

The steps to introduce a new product in the market are very different country to country, depending on the structure of their healthcare systems. We have conducted in the first quarter of 2021 a detailed assessment of the market opportunities and the complexity to enter the different European markets and decided to accelerate our activities in Italy, Spain, France and Poland. In those countries we are already in active discussion with potential distributors and early users of IndiTreat®, as we are in the Nordic countries, Sweden, Denmark, Finland and Norway. In parallel, we have started to prepare applications for reimbursement in Germany and UK, where the process is longer and more complex. We are in parallel addressing some smaller customer segments in which we expect to generate some sales during the second half of 2021.

ADAPTING TO THE UPCOMING REGULATORY CHANGES

In this first quarter we have started a project to make our operations and product technical files compliant with the new, much tighter EU Regulation 2017/746 that will come into force in May 2022. This is a significant challenge, not the least because of the lack of Notified Bodies to certify products under the new regulation. Anyway, we are getting ready for the change, and as part of the effort we have applied for ISO 13485 certification, which we expect to get in the second quarter of this year.

A NEW PHASE FOR THE COMPANY

In summary, we can say that the first quarter of 2021 has seen a decisive change in the orientation of the company, with a stronger focus in Business Development and Go-to-Market activities that we expect will show its results throughout the year in the form of the first commercial sales of IndiTreat® mCRC 3L.

Fernando Andreu, *CEO*
May 27th 2021

[1)] *American Society of Clinical Oncology. Annual meeting June 4-8 2021*

TICC TRIAL EXCEEDS GOALS AND UNLOCKS MARKET ACCESS PHASE

THE TICC TRIAL SURPASSES THE PRIMARY ENDPOINT

On March 1st 2021 2cureX received the positive news from our clinical partner at University Hospital Vejle that our interventional trial in metastatic colorectal cancer (mCRC) (NCT03251612, TICC) had met its primary endpoint.

The primary endpoint of the trial was related to Progression Free Survival (PFS) after 8 weeks of IndiTreat-guided treatment. PFS of placebo arms in randomized last-line trials is 20%. In the TICC the aim was to increase PFS to 40%. The final outcome of the trial was that PFS was raised even further to 50%.

"We are very pleased with IndiTreat®-guided treatment being able to surpass the primary end-point in these difficult to treat end-stage mCRC patients" says Henrik Harling, Chief Medical Officer, 2cureX.

The TICC trial was an Investigator Initiated Trial (IIT), meaning that the hospital partner is in control of the full process from writing and getting the clinical protocol approved to analysis and publication of results. In IITs the hospital is carrying a major part of the expenses.

The principal investigator of the TICC trial forwarded the TICC results in an abstract for presentation at ASCO (American Society of Clinical Oncology). The ASCO conference is the largest and most prestigious worldwide congress on Clinical Oncology, gathering over 30,000 physicians and health professionals from all over the world.

The ASCO meeting is held June 4-8, 2021.

ABSTRACT PUBLISHED MAY 19, 2021

All abstracts that were accepted by ASCO were published on May 19, 2021, two weeks before the ASCO conference. This allows 2cureX already now to dive a bit deeper into the results of the trial.

THE RESULTS OF THE TRIAL:

- Progression-Free-Survival after eight weeks of IndiTreat-guided treatment was 50%.
- The median PFS of patients undergoing IndiTreat®-guided third line treatment was 81 days and median overall survival (OS) was 189 days.
- The percentage of patients where needle biopsies from liver metastasis provided viable tumoroids allowing IndiTreat® testing was 54%. The technical aim of TICC was to reach 50%.

"We are very pleased with IndiTreat®-guided treatment being able to surpass the primary end-point in these difficult to treat end-stage mCRC patients"

Henrik Harling *(Chief Medical Officer)*

PERSPECTIVE OF THE RESULTS

The patients enrolled in the TICC trial had end-stage mCRC with a very poor prognosis. These patients had exhausted all standard treatments without slowing the progression of the disease.

The most prominent alternative to IndiTreat® for personalizing the treatment of this group of cancer patients is genomic profiling. A very recent review study (Haslam et al. Annals of Oncology, In press April 2021) published by ESMO (Eur. Soc. Medical Oncology) shows that the percentage of cancer patients with advanced or metastatic cancer who respond to genome-informed therapy is limited to 11,1%%.

The TICC trial shows that IndiTreat is able to identify treatments to which the patients respond positively at much higher percentage. 50% of the patients in the TICC trial thus experienced an improved response.

Genomics and cell-functional (IndiTreat®) testing provide complementary information on the cancer patient, and will in some cases synergize with each other. 2cureX will in those cases annotate the genomic information to get the highest performance of IndiTreat®.

THE TECHNICAL AIM OF THE TRIAL WAS ALSO MET

54% of the liver biopsies transferred to 2cureX contained viable cancer cells allowing tumoroids to be established, and an IndiTreat® test to be conducted. There is a direct correlation between the quality of the tissue sample (amount of living cancer cells) and the tumoroid viability.

The tissue samples in the TICC trial were needle biopsies from liver metastasis of heavily pretreated patients. Even under these very difficult conditions TICC was a technological success. Biopsy technologies are being developed fast due to the demand for quality biopsies from especially late-stage patients. 2cureX is following these developments closely.

INDITREAT IDENTIFIES THE MOST EFFICIENT TREATMENT

In the TICC trial we tested a panel of 15 drugs that has been on the market for a long time. The results clearly showed that IndiTreat® identifies the treatment that are the most efficient in the individual patient. However, IndiTreat® cannot improve the treatment beyond what the individual drug regimen is capable of in the best situation.

2CUREX WILL ADD NEW DRUG TREATMENTS TO THE INDITREAT TEST

The Food and Drug Administration (FDA) has in recent years approved an increasing number of drugs.

2cureX will on a continuous basis add new drug treatments to our IndiTreat® products, and thereby offer an expanded panel of treatment options to oncologists and patients.

2CUREX IN BRIEF

The key product of 2cureX is the IndiTreat® test, which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

For more details see 2cureX's website at ***www.2curex.com***

DECIDER –

IMPROVING CLINICAL DECISIONS IN OVARIAN CANCER

In Q1 2021 2cureX announced that it had been invited to become partner in the multinational 15 million EUR project, DECIDER under the EU Horizon 2020 research and Innovation program. 2cureX is to use its IndiTreat® test to identify medical treatments for ovarian cancer patients who have become resistant to standard treatments.

Ovarian cancer is often referred to as the "silent killer" to indicate that most women inflicted with the disease are diagnosed late in the disease development. 75% of patients are diagnosed with metastatic disease and 80% of these will develop chemo resistance.

The aim of the DECIDER project is via integration of multiple data levels to overcome chemotherapy resistance.

The goal of DECIDER is to develop diagnostic tools to identify earlier those patients that do not respond well to first-line treatment and to find alternative treatments for them.

The DECIDER project will interrogate multiple datasets e.g. genetic, cell-functional data and patient information with advanced data analysis and thereby provide an easy to use tool for oncologists to quickly design a treatment regime.

The project will also study the legal issues that impede or slow down the use of new treatments in order to facilitate commercialization and availability of personalized therapies in an ethically and legally sustainable manner.

HISTORICAL FLASHBACK –

2CUREX IS MOVING INTO ITS 15th ANNIVERSARY YEAR

2cureX was founded as a company in 2006 – the company is therefore moving into its 15th anniversary year.

2cureX was spun-out of the internationally recognized Carlsberg Research Center in late 2006. The center has strong scientific history within multiple research disciplines.

2cureX was based on a concept where drug candidates were integrated with cell functional screening in a proprietary screening platform, now named IndiTreat. The platform showed promise in drug discovery and clinical therapy design. An early start of Functional Precision Medicine.

At launch, 2cureX established a close collaboration with the University Hospital Bispebjerg (BBH) in Copenhagen and moved its laboratory activities to the hospital. BBH is a major colorectal cancer center in Denmark. The closeness to the clinic has been essential for the development of 2cureX including understanding the treatment workflow in a clinical setting.

Of the original three founders (Ole Thastrup, Grith Hagel and Timm Jessen), Ole and Grith are still members of 2cureX management.

The desire to build advanced cell-functional assay systems dates back to prior 2cureX, where Grith and Ole were founders of BioImage that was spun-out of Novo Nordisk. BioImage invented the enhanced Green Fluorescent Protein (eGFP) and a wealth of associated cell-functional assays. The company was sold to ThermoFischer in 2006.

Until listing at Nasdaq First North in November 2017, 2cureX has been financed by multiple international research grants and a dedicated group of private investors.

The vision of 2cureX to make cell-functional screening an integral part of cancer treatment is now becoming a reality with the launch of our first IndiTreat® product in metastatic colorectal cancer.

"2cureX has been through an exciting sometimes surprising journey, that now has crystallized into a unique ability to improve the treatment outcome and quality of life of colorectal cancer patients." Ole Thastrup.



DEVELOPMENT DURING THE FIRST QUARTER OF 2021, IN FIGURES

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website (www.2cureX.com).

NET SALES AND OPERATING INCOME

Net sales for the first quarter of 2021 amounted to 0 KSEK (0 KSEK). Other operating income for the first quarter amounted to 3 850 KSEK (2 603 KSEK).

FINANCIAL DEVELOPMENT

The result for the first quarter of 2021 amounted to -1 835 KSEK (-1 149 KSEK). The result for the period has been impacted by the conduct of clinical trials initiated to validate the IndiTreat® technology. A significant part of the clinical operations is funded by an EU grant called MicroCaT, recognized as Other operating income in the income statement.

LIQUIDITY

The Group's cash and cash equivalents amounted to 53 991 KESK (30 018 KSEK) as of March 31, 2021. Cash flow amounted to -4 995 KSEK (-5 452 KSEK). Cash flow from operating activities in the first quarter of 2021 amounted to -4 928 KSEK (-5 382 KSEK). The monthly average burn rate is approximately 2.1 MSEK, which is in line with the expectations.

SOLIDITY

The Group's equity ratio as of March 31, 2021 amounted to 94 percent (81).

THE SHARE

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of March 31, 2021, the number of shares amounted to 14 856 600 (12 420 000). The average number of shares during the first quarter of 2021 amounted to 14 856 600 (12 420 000).

EMPLOYEE STOCK OPTIONS

The Annual General Meeting on 28 May 2018 resolved to establish a Series 2018/2020 and a Series 2018/2021 warrant program for the Group's employees and key personnel. The employee warrants, totaling 360,000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period 28 May 2020 to 28 September 2020 and in the period 1 April 2021 to 28 September 2021, respectively. The warrant programs have been recalculated concerning exercise price and the number of shares each warrant entitles to subscribe for. The recalculation is due to the rights issue performed in 2019.

Each subscription warrant entitles the holder to subscribe for 1.06 share (before recalculation 1.0 share), at a subscription price of 8.40 SEK (before recalculation 8.86 SEK) per share. Upon full exercise of the issued warrants, the share capital would increase by 38,160 SEK (before recalculation 36,000 SEK). The employee warrants will be subject to the usual conversion terms in connection with new share issues etc.

The extraordinary general meeting on 5 November 2020 resolved to establish a warrant program for 3 new board members. The warrant program totaling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from 1 October 2023 up to an including 31 December 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price of 16,56 SEK.

Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc. The Group's result for Q1 2021 has been impacted by costs in the amount of 165 KSEK (47 KSEK) in the form of personnel costs.

POLICIES FOR THE PREPARATION OF THE INTERIM FINANCIAL REPORT

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

AUDITORS' REVIEW

This interim report has not been reviewed by the Company's auditors.

FINANCIAL CALENDAR

The Company prepares and publishes a financial report at the end of each quarter. Upcoming reports are planned to be released as follows:

- **Interim report Q2, 2021 . . . . 26/8-2021**
- **Interim report Q3, 2021 . . . 25/11-2021**
- **Year-end report, 2021 . . . . . 24/2-2022**

DELIVERY OF INTERIM REPORT

Landskrona, may 27, 2021 2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Jørgen Drejer
Member of the board

Camilla Huse Bondesson
Member of the board

Michael Lutz
Member of the board

Ole Thastrup
Member of the Board and CSO

Nils Brünner
Member of the board

Fernando Andreu
CEO

CERTIFIED ADVISER
Svensk Kapitalmarknadsgranskning AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

FINANCIAL OVERVIEW

FINANCIAL OVERVIEW THE GROUP

SUMMARY OF INCOME STATEMENT –THE GROUP (KSEK)	Q1 2021 1/1-31/3	Q1 2020 1/1-31/3	2020 1/1-31/12
Operating income			
Net sales	0	0	0
Other operating income	3 850	2 603	15 391
Total operating income	**3 850**	**2 603**	**15 391**
Operating expenses			
Other external expenses	-2 510	-2 154	-10 063
Personnel costs	-3 863	-2 931	-12 360
Depreciation of tangible fixed assets	-95	-90	-386
Total operating expenses	**-6 468**	**-5 175**	**-22 809**
Operating profit	**-2 618**	**-2 572**	**-7 418**
Financial posts	396	1 343	-1 173
Profit before tax	**-2 222**	**-1 229**	**-8 591**
Tax [1]	387	80	1 271
The result of the period	**-1 835**	**-1 149**	**-7 320**
Earnings per share (SEK)	-0,12	-0,09	-0,54
Average number of shares	14 856 600	12 420 000	13 604 775
No. of shares at the end of the period	14 856 600	12 420 000	14 856 600

[1] *This post refers to tax relief in subsidiaries regarding R&D work.*

SUMMARY OF BALANCE SHEET – THE GROUP (KSEK)	Q1 2021 1/1-31/3	Q1 2020 1/1-31/3	2020 1/1-31/12
Assets			
Fixed assets			
Tangible fixed assets	947	1 057	996
Total fixed assets	**947**	**1 057**	**996**
Current assets			
Receivables	5 980	2 440	3 471
Cash and bank balances	53 991	30 018	58 577
Total current assets	**59 971**	**32 458**	**62 048**
Total assets	**60 918**	**33 515**	**63 044**
Equity and liabilities			
Equity			
Share capital	1 486	1 242	1 486
Other contributed capital	75 388	38 023	75 388
Other equity	-17 900	-10 984	-10 690
The result of the period	-1 835	-1 149	-7 320
Total equity	**57 139**	**27 132**	**58 864**
Current liabilities			
Short-term liabilities [2)]	3 779	6 383	4 180
Total short-term liabilities	**3 779**	**6 383**	**4 180**
Total equity and liabilities	**60 918**	**33 515**	**63 044**

[2)] *This post includes prepaid contributions from the EU amounting to 0 KSEK (3 832 KSEK)*

SUMMARY OF CASH FLOW – THE GROUP (KSEK)	Q1 2021 1/1-31/3	Q1 2020 1/1-31/3	2020 1/1-31/12
Cash flow from operating activities	-4 928	-5 382	-11 694
Cash flow from investment activities	-27	-70	-403
Cash flow from financing activities	0	0	37 610
Cash flow for the period	**-4 955**	**-5 452**	**25 513**
Cash and cash equivalents at beginning of period	58 577	33 720	33 720
Exchange rate differences in cash and cash equivalents	369	1 750	-656
Cash and cash equivalents at the end of the period	**53 991**	**30 018**	**58 577**

CHANGE OF EQUITY – THE GROUP

1/1-2020 – 31/12-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2020)	**1 242**	**38 023**	**-3 256**	**-7 933**	**28 076**
Outline of previous year's results			-7 933	7 933	0
Rights issue	244	39 873			40 117
Issue costs		-2 508			-2 508
Allocation of staff warrants			399		399
Translation difference			100		100
The result of the period				-7 320	-7 320
At the end of the period (31/12-2020)	**1 486**	**75 388**	**-10 690**	**-7 320**	**58 864**

1/1-2021 – 31/3-2021

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**75 388**	**-10 690**	**-7 320**	**58 864**
Outline of previous year's results			-7 320	7 320	0
Allocation of staff warrants			165		165
Translation difference			-55		-55
The result of the period				-1 835	-1 835
At the end of the period (31/3-2021)	**1 486**	**75 388**	**-17 900**	**-1 835**	**57 139**

FINANCIAL OVERVIEW PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	Q1 2021 1/1-31/3	Q1 2020 1/1-31/3	2020 1/1-31/12
Operating income			
Net sales	0	0	0
Total operating income	**0**	**0**	**0**
Operating expenses			
Other external expenses	-301	-281	2 493
Staff costs	-261	0	0
Total operating expenses	**-562**	**-281**	**-2 493**
Operating profit	**-562**	**-281**	**-2 493**
Financial posts	68	188	465
Profit before tax	**-494**	**-93**	**-2 028**
Tax	0	0	0
The result of the period	**-494**	**-93**	**-2 028**

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	Q1 2021 1/1-31/3	Q1 2020 1/1-31/3	2020 1/1-31/12
Assets			
Fixed assets			
Financial assets	28 550	27 611	28 318
Total fixed assets	**28 550**	**27 611**	**28 318**
Current assets			
Receivables	353	267	305
Cash and bank balances	37 034	2 064	37 961
Total current assets	**37 387**	**2 331**	**38 266**
Total assets	**65 937**	**29 942**	**66 584**
Equity and liabilities			
Equity			
Share capital	1 486	1 242	1 486
Premium fund	79 588	42 223	79 588
Balanced result	-15 028	-13 517	-13 164
The result of the period	-494	-93	-2 028
Total equity	**65 552**	**29 855**	**65 882**
Current liabilities			
Current liabilities	385	87	702
Total short-term liabilities	**385**	**87**	**702**
Total equity and liabilities	**65 937**	**29 942**	**66 584**

SUMMARY OF CASH FLOW – PARENT COMPANY (KSEK)	**Q1 2021** 1/1-31/3	**Q1 2020** 1/1-31/3	**2020** 1/1-31/12
Cash flow from operating activities	-927	-470	-2 183
Cash flow from investment activities	0	0	0
Cash flow from financing activities	0	0	37 610
Cash flow for the period	**-927**	**-470**	**35 427**
Cash and cash equivalents at beginning of period	37 961	2 534	2 534
Cash and cash equivalents at the end of the period	**37 034**	**2 064**	**37 961**

CHANGE OF EQUITY – PARENT COMPANY

1/1-2020 – 31/12-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2020)	**1 242**	**42 223**	**-11 646**	**-1 917**	**29 902**
Outline of previous year's results			-1 917	1 917	0
Rights issue	244	39 873			40 117
Issue costs		-2 508			-2 508
Allocation of staff warrants			399		399
The result of the period				-2 028	-2 028
At the end of the period (31/12-2020)	**1 486**	**79 588**	**-13 164**	**-2 028**	**65 882**

1/1-2021 – 31/3-2021

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**79 588**	**-13 164**	**-2 028**	**65 882**
Outline of previous year's results			-2 028	2 028	0
Allocation of staff warrants			165		165
The result of the period				-494	-494
At the end of the period (31/3-2021)	**1 486**	**75 388**	**-15 028**	**-494**	**65 552**

THE POWER OF PRECISION. FOR EVERY ONCOLOGIST. TODAY.



2CUREX AB (publ)

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark
Phone: +45 2211 5399 / E-mail: info@2curex.com